NIMG-26. EVALUATING THE DAYS GAINED RESPONSE METRIC IN CLINICAL TRIALS USING BEVACIZUMAB PLUS ADDITIONAL AGENTS FOR RECURRENT GLIOBLASTOMA

Determining effective therapies for patients with recurrent glioblastoma remains difficult especially in small early phase clinical trials. Currently utilized estimators of treatment response rely on two-dimensional measurements of tumor progression (e.g. RANO, RECIST, MacDonald) that have often fal...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Neuro Oncol
Main Authors: Singleton, Kyle, Johnston, Sandra, Rickertsen, Cassandra, Keith Anderson, S, De Leon, Gustavo, Whitmire, Scott, Clark-Swanson, Kamala, Bendok, Bernard, Mrugala, Maciej, Porter, Alyx, Galanis, Evanthia, Swanson, Kristin
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2019
Assuntos:
Neuro-Imaging
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6847498/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noz175.697
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados